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The golden era of antibiotics, heralded by the discovery of penicillin, has long been
challenged by the emergence of antimicrobial resistance (AMR). Host defense peptides
(HDPs), previously known as antimicrobial peptides, are emerging as a group of
promising antimicrobial candidates for combatting AMR due to their rapid and unique
antimicrobial action. Decades of research have advanced our understanding of the
relationship between the physicochemical properties of HDPs and their underlying
antimicrobial and non-antimicrobial functions, including immunomodulatory, anti-biofilm,
and wound healing properties. However, the mission of translating novel HDP-derived
molecules from bench to bedside has yet to be fully accomplished, primarily attributed
to their intricate structure-activity relationship, toxicity, instability in host and microbial
environment, lack of correlation between in vitro and in vivo efficacies, and dwindling
interest from large pharmaceutical companies. Based on our previous experience and
the expanding knowledge gleaned from the literature, this review aims to summarize
the novel strategies that have been employed to enhance the antimicrobial efficacy,
proteolytic stability, and cell selectivity, which are all crucial factors for bench-to-bedside
translation of HDP-based treatment. Strategies such as residues substitution with natural
and/or unnatural amino acids, hybridization, L-to-D heterochiral isomerization, C- and
N-terminal modification, cyclization, incorporation with nanoparticles, and “smart design”
using artificial intelligence technology, will be discussed. We also provide an overview of
HDP-based treatment that are currently in the development pipeline.
Keywords: antibiotic, antimicrobial peptide, antimicrobial resistance, artificial intelligence, host defense peptide,
nanoparticle, peptide
INTRODUCTION
Antimicrobial resistance (AMR) currently represents amajor global health threat of the twenty-first
century and is estimated to cost 10 million deaths per year by 2050 (1, 2). Tackling AMR requires
a multi-faceted and synergistic approach, including understanding of the main mechanisms and
drivers of AMR at the microorganism, individual and population levels, antimicrobial stewardship
within the healthcare and agriculture sectors, in tandem with discovery and development of new
classes of antimicrobial therapy (3, 4).
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Host defense peptides (HDPs), also known as antimicrobial
peptides, are a group of evolutionary conserved molecules
that play critical roles in the innate immune system (5–7).
These molecules are usually small in size (around 12–50 amino
acid residues), cationic (with a net charge of +2 to +13),
and amphiphilic geometry (5, 6). So far, more than 3,000
naturally occurring and synthetic HDPs have been discovered
across six life kingdoms (8, 9), underlining their essential roles
during the adaptation and evolutionary process. HDPs have
been shown to exhibit broad-spectrum antimicrobial activities
against a plethora of microorganisms, including drug-resistant
bacteria, fungi, parasites, and viruses (5, 10). In contrast
to conventional antibiotics (which usually target a particular
extracellular or intracellular binding site), cationic HDPs bind
to the anionic surfaces of bacteria causing lytic cell death
through varied mechanisms. Additionally, HDPs could also kill
bacteria via inhibition of macromolecules that are involved in
the biosynthesis of the surface membrane, and components of
metabolic organelles (11, 12). Such unique mechanism of action
accounts for the rapid and broad-spectrum antimicrobial action
and the low risk of developing AMR as modification of the entire
microorganisms’ anionic membrane incurs a substantially higher
fitness cost when compared to alteration of a particular binding
site targeted by the conventional antibiotics (e.g., alteration in the
30S subunit inhibits the action of aminoglycosides) (13).
In addition to the antimicrobial activity, there has been
emerging evidence highlighting the non-antimicrobial roles of
HDPs, including antibiofilm (14), immunomodulatory (15),
wound healing (16), anti-viral, and anti-cancer properties
(17), rendering them an attractive and novel class of clinical
therapeutics (18). For instance, corneal infection or infectious
keratitis is a sight-threatening ocular disease that can be caused
by a wide range of microorganisms, including bacteria, fungi,
parasites, and viruses (19, 20). In addition, corneal infection
may be caused by polymicrobial infection which can present
significant therapeutic challenges to the clinicians (21). The dual
broad-spectrum antimicrobial and wound healing properties of
HDPs would not only provide a comprehensive antimicrobial
coverage for the infection but also expedite the healing process
of corneal ulceration, limiting the damage to the cornea and
ultimately preserving the vision. The complete repertoire of
antimicrobial and non-antimicrobial functions of HDPs has
been recently summarized in a seminal review by Mookherjee
et al. (22).
Despite decades of research efforts have been invested in
the field of HDP, the mission of translating novel HDP-derived
molecules from bench to beside has yet to be fully accomplished.
The sluggishness in the HDP-derived drug development pipeline
is primarily attributed to their complex structure-activity
relationship (SAR), undesired toxicity to host tissues, instability
in host and microbial environment, lack of correlation between
in vitro and in vivo efficacies, and dwindling interest from
large pharmaceutical companies (23–26). A list of synthetic
derivatives of HDPs that are currently under clinical trials
are summarized in Table 1 for readers’ convenience. Detailed
overview on the mechanisms of actions and clinical applications
of HDPs have also been provided elsewhere in published review
articles (27–29). Based on the literature and our experience,
this review article aims to highlight the strategies that have
been attempted to enhance the antimicrobial efficacy, proteolytic
stability, and cell selectivity (for microbial cells instead of host
cells; i.e., improved safety) of HDPs, which are all important
factors to be considered during the translation of thesemolecules.
STRATEGIES FOR ENHANCING
ANTIMICROBIAL EFFICACY AND SAFETY
OF HDPs
Structurally, HDPs are mainly characterized by the presence
of key charged residues (e.g., Arg and Lys), with a high
proportion of hydrophobic residues (constituting 50% or more)
and amphipathicity (7, 30). Optimization of HDP sequences
to improve antimicrobial efficacy has been previously detailed
(30, 31). Here, we aim to provide key strategies to improve
the selectivity of HDPs toward microbial membranes through
reported examples of model HDPs that were enhanced through
rational design approaches (Table 1).
Residue Substitution With Natural Amino
Acids (AAs)
HDPs should fulfill key functional requirements to qualify
for clinical use, including low toxicity, high antimicrobial
activity, and good in vivo stability (24). These requirements are
closely linked to their biochemical selectivity toward anionic
and zwitterionic surfaces (24). The antimicrobial activity is
attributed to a fine balance of hydrophobicity, cationic residues,
amphipathicity, and structural conformation (e.g., α-helical, β-
sheet, and cyclized) (32). On the other hand, the hydrophobic
interaction between specific residues of HDPs (e.g., Leu, Ile,
Val, Phe, Tyr, Trp) and zwitterionic phospholipids on host cell
surfaces is responsible for its toxicity. For example, peptide
derivatives of mastoparan (a key constituent of wasp venom) that
were designed based on fixed five rules utilizing the quantitative
structure-activity relationship (QSAR) approach showed potent
antimicrobial efficacy against Bacillus subtilis (33). It was shown
that the potency of these derivatives was mainly dependent on
the presence of Trp, Lys, and His (33). Lata et al. (34) analyzed
486 HDPs from the antimicrobial peptide database (APD) for
AA frequency in these sequences using the bioinformatic tools.
Residues such as Gly, Arg, Lys, and Leu were shown to be
commonly found in HDPs, whilst AAs such as Ser, Pro, Glu,
and Asp were least common at both N- and C-terminus. A
recent study from Hilpert group has demonstrated through in
silico designed library of 3,000 de novo short peptides (9-mer
in length) that the specific design characteristics of HDPs did
not apply to short peptides (35). The peptide sequences that
were grouped as “super active” based on their activity toward
Pseudomonas aeruginosaweremainly composed of Lys, Arg, Trp,
andVal/Ile/Leu (35). However, the activity of these super peptides
toward host cells and in vivo stability was not yet reported.
Melittin, a key constituent of honey-bee venom, is a potent
HDP with strong antimicrobial activity (36). However, its clinical
use is largely limited by the high hemolytic activity (36). Blondelle
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TABLE 1 | Derivatives of host defense peptides in clinical trials.
Drug/peptide
name
Peptide derivative Progress Application References/Trial registry (Status; Last update
posted)
Omiganan
(CLS001/MBI226)
Indolicidin Phase II/III Facial seborrheic dermatitis; Genital warts;
Rosacae; Vulvar neoplasia; Atopic dermatitis;
Acne vulgaris; Skin antisepsis; Prevention of
catheter infections
NCT03688971 (recruiting; May 2019)
NCT02576847 (completed; Jul 2018)
NCT02547441 (completed; Jul 2018)
NCT02576860 (completed; Mar 2018)
NCT03091426 (completed; Dec 2017)
NCT02596074 (completed; Aug 2017)
NCT03071679 (completed; May 2017)
NCT02571998 (completed; Mar 2017)
NCT02849262 (completed; Mar 2017)
NCT02456480 (completed; Jul 2016)
NCT02066545 (completed; Sept 2015)
NCT01784133 (completed; May 2015)
NCT02028286 (completed; Apr 2014)
NCT00608959 (completed; Jan 2010)
NCT00231153 (completed; Aug 2009)
NCT00027248 (completed; Sept 2005)
Pexiganan
(MSI-78)
Magainin Phase III Diabetic foot ulcer (topical) NCT01594762 (completed; Jun 2017)
NCT01590758 (completed; Jun 2017)
NCT00563433 (completed; Nov 2007)
NCT00563394 (completed; Nov 2007)
Iseganan
(IB-367)
Protegrin Phase II/III Prevention of radiation-induced oral mucositis;
Ventilator-associated Pneumonia
NCT00022373 (unknown; Oct 2014)
NCT00118781 (terminated; Jul 2005)
(failed in Phase III; https://www.thepharmaletter.com/
article/intrabiotics-lead-drug-hits-snag-in-phase-iii)
C16G2 Novispirin G10 Phase II Dental cavities NCT02594254 (completed; Aug 2019)
NCT02509845 (completed; Aug 2019)
NCT03196219 (completed; Aug 2019)
NCT02254993 (completed; Aug 2019)
NCT03052842 (completed; Aug 2019)
NCT03004365 (completed; Aug 2019)
NCT02044081 (completed; Aug 2019)
Brilacidin
(PMX-30063)
Defensin mimetic Phase I/II Prevention of radiation-induced oral mucositis,
treatment of gram-positive bacterial skin
infections
NCT04240223 (completed; Feb 2020)
NCT02324335 (completed; Jan 2019)
NCT02052388 (completed; Sep 2018)
NCT01211470 (completed; May 2012)
Novexatin
(NP213)
Polyarginine cyclic HDP Phase II Onychomycosis (topical) www.novabiotics.co.uk (no registered trial)—PMID
32232410
PAC-113 Histatin-3 Phase IIb Oral candidiasis (mouth rinse) NCT00659971 (completed; Jun 2008)
hLF1−11 Human lactoferrin Phase II Bacteraemia; Candidemia; anti-infectives for
haematopoietic stem cell transplant recipients
NCT00430469 (withdrawn; Jun 2015)
NCT00509834 (withdrawn; Jun 2015)
NCT00509847 (withdrawn; May 2014)
NCT00509938 (completed; Oct 2008)
OP-145
(AMP60.4Ac)
Human LL-37 Phase II Chronic suppurative otitis media ISRCTN12149720 (completed; Feb 2019)
ISRCTN84220089 (completed; Jan 2008)
Glutoxim
(NOV-002)
Synthetic hexapeptide Phase II/III Tuberculosis; myelodysplastic syndromes;
ovarian cancer; non-small cell lung cancer;
breast cancer;
NCT00960726 (withdrawn; Jul 2012)
NCT00499122 (completed; Jan 2018)
NCT00347412 (completed; Nov 2011)
NCT00345540 (completed; Mar 2015)
Lytixar
(LTX-109)
Synthetic peptidomimetic Phase I/IIa Impetigo; drug-resistant gram-positive nasal
and skin infections (topical); atopic dermatitis
NCT01158235 (completed; Jun 2011)
NCT01223222 (completed; Feb 2011)
NCT01803035 (completed; Apr 2014)
Opebacan
(rBPI-21)
Bactericidal/permeability
increasing protein (BPI)
Phase I/II Prevention of endotoxemia following
myeloablative allogeneic stem cell
transplantation; anti-sepsis in patients with
burn injury
NCT00454155 (terminated; Jul 2012)
NCT00462904 (terminated; Nov 2019)
et al. (37) studied the function of Trp in melittin activity
through serial Trp substitution starting from N- to C-terminus.
Substitution of Leu→ Trp at 9th position was shown to decrease
the hemolytic activity whereas substitution of Pro→ Trp at 14th
position improved the alpha-helical conformation and reduced
the hemolytic effects compared to parent melittin peptide.
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HDPs with Pro residues are widely known to display a
disrupted helix conformation, which eventually affects their
surface retention time and penetration into microbe cytoplasm
(38, 39). A recent study using peptide analog (Anal 3, 19-AA
long) from N-terminus of Helicobacter pylori ribosomal protein
L1 has demonstrated that an insertion of Pro-hinge into Anal
3 (via Glu→ Pro substitution at 9th position) significantly
improves the peptide selectivity toward microbes with no effect
on host cells (40, 41). This was attributed to the helix-hinge-
helix conformation of Anal 3-Pro analog at the surface of bacteria
allowing peptide penetration and DNA binding in the cytoplasm.
This study suggested that rational insertion of Pro residue
through SAR analysis could improve the biological membrane
selectivity of microbicidal peptides. Proline-rich designed HDPs
such as ARV-1502 (42), oncocin (43), and Bac-5 (44, 45) have
shown significant efficacy against Gram-negative pathogens but
not host cells membranes. Unlike cationic HDPs, proline-rich
peptides kill bacteria through inhibition of protein synthesis
(12, 45–47). Histidine-rich (48, 49), alanine-rich (50), and
tryptophan-rich (51) short HDPs have also been developed.
These were shown to be highly effective at acidic pH against a
range of Gram-negative and Gram-positive bacteria (52).
Magainin-2 is 23 residues long antimicrobial peptide (AMP)
isolated from frog skin, Xenopus laevis (53). Due to its
non-hemolytic and broad-spectrum antimicrobial properties,
magainin-2 was widely studied as a model peptide to understand
the SAR of naturally occurring AMPs (54–58). Chen et al.
(59) have demonstrated that the alpha-helical conformation of
magainin-2 could be stabilized through Gly→ Ala substitution
(at both 13th and 18th position) and C-terminal amidation.
This was shown to increase the antibacterial activity by 2-
fold against a range of bacteria without modulating its safety
against erythrocytes (59). Numerous groups have made attempts
to improve the activity of magainin-2 against Gram-negative
bacteria through residue substitution. It was demonstrated
that the substitution of Phe→ Trp in magainin-2 (F12W
mutant) increased its activity against Gram-negative bacteria;
however, this increased its selectivity toward erythrocytes,
causing significant hemolysis (60). This could be attributed to
the bulkiness of Trp compared to Phe and the presence of
NH-group in Trp that is capable of forming hydrogen bonds
with zwitterionic phospholipids (39, 61). Further modification
through reduction of net charge of F12W mutant (Lys→ Glu
substitution at 10th position) was shown to reduce the hemolytic
effect. However, this made the mutant magainin-2 less effective
against Gram-negative bacteria (60). Extensive SAR studies from
Zasloff ’s laboratory led to the development of MSI-78 (also
known as pexiganan), a derivative of magainin-2, which showed
improved safety/efficacy profile compared to parent magainin-2
sequence (62, 63). However, it failed in the phase III clinical trial
for the treatment of infective diabetic foot ulcers. Further details
on pexiganan clinical journey can be reviewed elsewhere (64–66).
Typically, natural HDPs display a net positive charge between
+2 and +13. It has been widely demonstrated that modification
of total net charge of synthetic HDPs through cationic residue
substitution enhances electrostatic interaction between HDPs
and lipopolysaccharide (LPS) (30, 60). However, this approach
has shown to increase the toxicity of certain HDPs. For example,
magainin-2 analogs with positive charge above +5 were shown
to display hemolytic effects (rank order +6 > +5 > +4 >
+3) (67). To overcome the inherent issues associated with
peptide optimization, Mishra and Wang (68) adopted an
ab initio design approach which involved utilization of novel
database-filtering technology (DFT). This led to the development
of a 13-AA long, leucine-rich, anti-MRSA peptide template—
termed “DFTamP1” (68). A subsequent study demonstrated that
DFT503, an optimized variant of DFTamP1, was shown to be
safe and effective in in vivo killing of MRSA in a neutropenic
mouse model. This anti-MRSA activity was attributed to its
eight Leu residues and a single Lys at position 11 (net charge
+1) (69). These studies suggested that lower cationic charge
and high hydrophobicity is preferred for anti-MRSA synthetic
peptides. This strategy could form the basis for the development
of species-specific peptide-based therapy against multidrug
resistant (MDR) pathogens.
LL-37 is a lone member of the cathelicidin family of HDPs
reported in humans (70–72). It was widely studied due to
its multi-functional abilities, including microbicidal (73), anti-
cancer, immunomodulatory (74), chemotactic (75), and wound-
healing properties (76). Numerous groups have exploited the
structure of LL-37 to design a range of synthetic antimicrobial
analogs through residue substitution (77, 78). FK-13 (residues
17-29 of LL-37) was identified as a core antimicrobial and
anti-cancer domain using nuclear magnetic resonance (NMR)
technique (79). Subsequently, the deletion of Phe at 17th
position led to the development of KR-12, which showed potent
antimicrobial efficacy equivalent to LL-37 and FK-13 against
Escherichia coli, but devoid of toxic activity against host cells (80).
KR-12 and KE-18 analogs were recently shown to possess anti-
Candida and anti-Staphylococcal properties (81). Specifically, KE-
18 showed anti-biofilm activity even at sub-killing concentration
against yeast and bacteria (81). Further variants of KR-12
were also reported and the less cationic analogs, a5 and a6,
were shown to possess potent immunomodulatory, antibiofilm,
antimicrobial, and osteogenic properties (82–85). Variants of
LL-23, corresponding to 23 N-terminal residues of LL-37, were
generated through substitution of Ser→ Ala and Ser→ Val at
the 9th position. LL-23V9 peptide was shown to display increased
antimicrobial and immunosuppressive activities compared to LL-
23 and parent LL-37 (86).Wang et al. (77),Mishra andWang (87)
have recently demonstrated that titanium surface immobilized
FK-16 (a short variant of LL-37) is highly antimicrobial against
ESKAPE pathogens. Our group has recently demonstrated that
FK-16 could be used for repurposing conventional antibiotics
such as vancomycin as a strategy to counter antimicrobial
resistance (88). Further improvement of FK-16 by Narayana et al.
(89) have also led to the development of GF-17, 17BIPHE2, and
other related variants of superior efficacy and safety compared
to LL-37. Nell et al. (90) designed a range of short peptides
through residue substitution based on the LL-37 sequence
for neutralization of lipopolysaccharide (LPS) and lipoteichoic
acid (LTA). P60.4, a 24-AA derivative, was shown to possess
similar LPS/LTA neutralization ability and antimicrobial effects
compared to LL-37, but with negligible in vivo toxicity toward
Frontiers in Immunology | www.frontiersin.org 4 May 2020 | Volume 11 | Article 983
Ting et al. Therapeutic Potentials of Host Defense Peptides
audible canal, skin, and eyes. This peptide was subsequently
termed as OP-145 and was proven to be safe and efficacious in
the treatment of chronic otitis media in phase I/II clinical trials
(91). However, the activity of OP-145 was recently shown to
be reduced in human plasma (92). Subsequent modification led
to the development of synthetic antimicrobial and antibiofilm
peptides (SAAPs) such as SAAP-145, −148, and −276, which
showed potent anti-biofilm activity against a range of MDR
pathogens (92).
Residue Substitution With Unnatural AAs
HDPs are essentially a group of small bioactive molecules
made of different combinations of 20 naturally occurring
AAs. The nearly infinite chemical space (20n) and varying
physicochemical properties account for the vast structural
and functional diversities of naturally occurring HDPs (8, 9).
However, susceptibility to host cell interaction (e.g., human
erythrocytes, albumin, etc.) (93, 94) and proteolytic degradation
from the host and bacterial proteases (e.g., human proteases in
serum, staphylococcus aureolysin, pseudomonas elastase, etc.)
(95–98) remains one of the key impediments in translating
HDP-based treatment to clinical therapeutics. For instance,
the anti-staphylococcal activity of cathelicidin (LL-37)—one
of the most widely studied human HDPs—was shown to be
inhibited by the proteases produced by Staphylococcus aureus,
namely the aureolysin (a metalloproteinase) and V8 protease
(glutamylendopeptidase), via cleavage and hydrolysis of the
intramolecular peptide bonds (96).
To overcome this barrier, incorporation of unnatural or non-
proteinogenic AAs has been employed to increase the proteolytic
stability and/or antimicrobial efficacy of HDPs. It is known
that the antimicrobial efficacy of HDPs is greatly influenced
by the cationicity (99). To preserve the cationicity and thence
efficacy, researchers have attempted to optimize the HDPs by
replacing the cationic residues (e.g., lysine) with its analogs such
as ornithine, 2,4-diamino-butyric acid (DAB), and 2,3-diamino-
propionic acid (DAP), which have three, two, and one methylene
(CH2) groups in the side chain, respectively (100, 101). Using
Trp-rich peptides as the design template, Arias et al. (101)
reported a 4-fold length-dependent increase in the antibacterial
activity against E. coliwhen the side chain of lysine was shortened
from 4-carbon (lysine) to 1-carbon (DAP). Such effect was likely
attributed to an increase in membrane permeabilization based
on calcein leakage study. In addition, a substantial improvement
in the stability against trypsin was observed when the side
chain of arginine or lysine was shortened (101). Oliva et al.
(102) investigated the potential role of integrating unnatural
AAs within the 9-residue synthetic HDPs and discovered that
unnatural AAs such as 2-naphthyl-L-alanine (an aromatic
residue) and S-tert-butylthio-L-cysteine residues enhanced the
antimicrobial efficacy and proteolytic stability in 10% serum
for 1 and 16 h (to a lesser extent). In addition, incorporation of
unnatural AAs dipeptides (tetrahydroisoquionolinecarboxylic
acid-octahydroindolecarboxylic acid; or Tic-Oic) within
magainin analogs has been shown to induce an amphipathic
and loose alpha-helical structure with enhanced antimicrobial
potency and selectivity against Gram-positive, Gram-negative
and mycobacterium (103).
Unnatural AAs have been successfully utilized for improving
the efficacy and stability of various peptidomimetics (104). For
example, Saralasin, a partial angiotensin II receptor agonist, was
developed by incorporation of sarcosine (an unnatural AA) at
a key position in angiotensin II molecule (105). This provided
resistance against aminopeptidases and improved bioactivity.
Carbetocin, a cyclic 8-AA derivative of oxytocin is currently used
for the treatment of post-partum hemorrhage, was developed
through incorporation of unnatural AAs such as methyltyrosine
which improved its metabolic stability and overall therapeutic
benefits (106).
Hybridization
It is widely known that a cocktail of HDPs are produced at
the tissue sites in response to infection (107, 108). This natural
synergism between HDPs was shown to be beneficial to the
host, providing the first line of defense against pathogens. This
was very well-exploited through in vitro and in vivo studies,
which proved that the combination of two HDPs produces
strong activity against bacteria (107, 108). However, this was
not deemed as a cost-effective approach and the issue of
host toxicity remains unresolved. Hybridization strategy was
shown to circumvent these known issues, which involves the
combination of key residues from two to three HDPs of different
mechanisms of actions into a single sequence (109–111). In
1989, Boman et al. (112) elegantly showed that a hybrid of
cecropin-A (1-13) and melittin (1-13) was highly bactericidal
and less toxic toward host cells compared to parent cecropin-A
and melittin. Subsequent modifications led to the development
of numerous short hybrids of cecropin-A and melittin (15–18
residues in length), which showed similar activity as the first-
generation hybrids (113, 114). Chimeras of cecropin-A (CA)
and magainin-2 (MA) were also developed that exhibited potent
antibacterial and antitumor activities. Insertion of hydrophobic
residues through residue substitution in the hinge region (at 16th
position) of CA(1-8)-MA(1-12) hybrid was shown to improve
its antibacterial and antitumor activity with no hemolytic effects
(115). A recent study has demonstrated that substitution of key
residues in CA(1-8)-MA(1-12), specifically Phe5Lys, Lys7His,
Phe13His, Leu14Phe, and His17Leu, could stabilize the alpha-
helical conformation, resulting in improved LPS binding affinity,
increased bactericidal activity against clinical Gram-negative
isolates, and low cytotoxicity (116). Hybrids of human-derived
and animal-derived HDPs were also developed to comprise the
membrane-lytic and immunomodulatory properties of cationic
HDPs. For example, hybrids of cecropin-A (1-8)-LL37(17-20)
(117), melittin(1-13)-LL37(17-30) (118), and BMAP27(9-20)-
LL37(17-29) (119) were shown to be highly bactericidal and
improved the efficacy of conventional antibiotics against a
variety of bacteria. Another study involving “triple hybrid” of
cecropin-A, melittin, and LL-37 showed that this approach could
significantly enhance the bactericidal against a range of Gram-
negative and Gram-positive organisms (120). Similarly, Dutta
et al. (121) reported good in vitro and in vivo efficacies of
an antimicrobial contact lens coated with melimine (derived
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from melittin and protamine) for treating infectious keratitis
in a rabbit model. These studies have clearly indicated that an
optimized rational design approach could enable development of
chimeras with improved biological selectivity.
In addition to overcoming the issue of host toxicity
(as described above), the hybrid strategy has also led to
the development of numerous species-specific and targeted
bactericidal peptides to prevent damage to useful microbiome
(122–124). Kim et al. (122) have developed a targeted chimeric
peptide for the treatment of P. aeruginosa infection. Through
phage-display library screening, they identified an outer-
membrane porin F (OprF) binding peptide motif, termed PA2.
Hybridization of this tag sequence to a membrane-lytic short
peptide, GNU-7, was shown to improve the antimicrobial efficacy
of parent GNU-7 by 16-fold toward P. aeruginosa both in in vitro
and in vivo model systems. LPS-targeting GNU-7 variants were
also developed through hybridization with lactoferrin (28-34),
BPI (84-99), and de novo sequence (125). Chimeric bactericidal
peptides targeted to E. faecalis (123) and S. mutans (124) were
also developed based on the species-specific pheromones. This
approach was proven to be highly targeted and would prevent
the damage to commensal microbes.
L-to-D Heterochiral Isomerization
Depending on the geometric arrangement, all naturally occurring
AAs (except for glycine) can exist as stereoisomers, either
in L- or D-form, albeit only the L-configuration can be
utilized by cells (126). That said, there is emerging evidence
showing that most organisms are able to produce D-AAs,
primarily through spontaneous racemization of L-AAs or post-
translational enzymatic modification (127). In addition, D-
AAs such as D-alanine and D-glutamic acid are found in
peptidoglycan, which is a key component of the cell wall of Gram-
positive bacteria. These D-AAs have been shown to increase
resistance to host proteases that usually cleave the peptide bonds
between L-AAs, thereby maintaining their virulence (126).
Capitalizing on the evolutionarily advantageous strategy
equipped by microbes, L-to-D isomerization has been utilized
to enhance the proteolytic stability of HDPs against a range of
host and microbes’ proteases (128–133). L-to-D isomerization
can be utilized to either modify specifically one or several
L-AAs (131, 134), or the entire sequence of a L-form HDP
(130–132). Carmona et al. (130) demonstrated that L-to-D
isomerization of Panidin-2 (D-Pin2) improved the cell selectivity
(i.e., reduced hemolysis) and proteolytic stability in human
serum, elastase, and trypsin, while maintaining the antimicrobial
activity against a range of Gram-positive and Gram-negative
bacteria. In a similar vein, Jia et al. (131) reported an improved
stability of D-AA derivative of polybia-CP (which was originally
derived from the venom of social wasp Polybia paulista), in
chymotrypsin and trypsin for 1 and 6 h and reduced hemolytic
activity (D-lysine derivative). In addition to the beneficial effect
of proteolytic stability and/or cell selectivity, the D-form AAs
may enhance the antimicrobial efficacy of HDPs. For example,
the D-form KLKLLLLLKLK-NH2 (derived from sapesin B) was
shown to exhibit increased antimicrobial efficacy against S.
aureus (due to increased interaction with the peptidoglycan),
E. coli and Candida albicans when compared to the L-form
(132). However, the enhanced antimicrobial efficacy was not
observed in other tested D-forms of HDPs such as mastoparan
M and temporin A, suggesting that the D-isomerization effect is
sequence-dependent (132).
L-to-D isomerization has also been shown to confer unique
changes to the peptide-folding and secondary structure of HDPs
(128, 131, 133). Based on circular dichroism analysis, the D-form
derivatives of naturally occurring alpha-helical HDPs typically
exhibit a left-hand alpha-helical spectrum (instead of a right-
hand spectrum) whereas partial D-isomerization of HDPs may
result in some degree of loss of alpha-helicity, depending on the
position and number of D-AAs being introduced (128, 131, 133).
Such changes in the secondary structure are likely accountable for
the reduced host toxicity and improved cell selectivity in some
HDPs (131).
This strategy was found to be successful in the development
of daptomycin, an antibacterial cyclic lipopeptide, which was
approved by the US Food and Drug Administration (FDA)
in 2003 for the treatment of skin and systemic Gram-positive
infections (104, 135). Structurally, daptomycin is comprised of
13 residues including D-alanine and D-serine (134). In addition,
it also contains non-canonical amino acids such as ornithine,
L-kynurenine, and L-3-methylglutamic acid (134).
C- and N-Terminal Modification
A range of N- and C-terminal modification strategies have
been proposed to enhance the antimicrobial efficacy and/or
cell selectivity of natural and synthetic HDPs (102, 136,
137). Amongst all, N-terminal acetylation (CH3CO-) and C-
terminal amidation (-NH2) are the two most commonly
attempted strategies (102). N-acetylation is a common protein
modification observed in eukaryotic and prokaryotic cells (138).
By neutralizing the positive charge (NH+3 ) at the N-terminal, N-
acetylation can result in a range of irreversible changes to the
protein properties, including the folding, stability, and protein-
protein interactions (138). Saikia et al. (139) examined the
antimicrobial efficacy and salt sensitivity of E. coli-derived MreB
(a bacterial cytoskeleton protein found in non-spherical cells)
and its N-acetylated analogs and found that N-acetylated W-
MreB1−9 demonstrated a higher antimicrobial efficacy (in salt)
compared to W-MreB1−9. However, N-acetylation may result in
a decrease in antimicrobial efficacy of certain synthetic HDPs due
to a reduction in the overall cationicity (139, 140), suggesting
that the benefit of this modification strategy is only selective for
certain HDPs.
On the other hand, C-amidation is a common post-
translational modification that is widely observed in nature,
including the natural synthesis of HDPs (137). C-amidation has
been shown to improve the antimicrobial efficacy of certain
HDPs, including aurein (141), melittin (142), modelin-5 (143),
anoplin (144), and esculentin-1 (145), amongst others. The
enhanced antimicrobial efficacy of these HDPs is likely ascribed
to the increased alpha-helix stability at the peptide-membrane
interfaces, enabling a greater membrane disruption and pore
formation (141–144). In addition, Oliva et al. (102) demonstrated
that simultaneous N-acetylation and C-amidation enhanced the
proteolytic stability of HDP derived from human apolipoprotein
B by more than 4-fold when exposed to fetal bovine serum 10%
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for 1 h. Similarly, the proteolytic stability of tachyplesin I (a beta-
hairpin HDP from the horseshoe crab, Tachypleus tridentatus) in
fresh human serum was significantly enhanced using the similar
N-acetylation and C-amidation strategy (146).
Other N- or C-terminal modification strategies have also
been described in the literature, including N-methylation of
certain cyclic HDPs to enhance the antimicrobial efficacy (136),
introduction of 6-aminocaproic acid at the N- and C-terminals
to protect HDPs from the action of exopeptidases (102, 147),
and pegylation of the C-terminus of M33, a branched peptide,
to increase the resistance against P. aeruginosa elastase (148).
Cyclization
Cyclization is a common phenomenon observed in natural HDPs
that can exist in three main forms: (a) sidechain to sidechain;
(b) backbone to backbone; and (c) sidechain to backbone (137).
It has been shown to demonstrate several favorable biological
properties, including enhanced antimicrobial efficacy, stability
against proteases (due to conformational rigidity), enhanced cell
selectivity, and reduced host toxicity (137, 149), rendering it an
attractive strategy for translating HDPs from bench to bedside.
Some of the notable examples of cyclic glyco- or lipopeptides
that are already in clinical use include vancomycin, daptomycin,
and colistin/polymyxin, which are commonly used as last
resorts for combatting MDR bacteria, albeit their widespread
use are hindered by the inherent toxicity and emergence of
AMR (149–151).
In view of the structural stability, Dathe et al. (152) were
able to create a series of short cyclic hexapeptides (based on
AcRRWWRF-NH2) with enhanced antimicrobial efficacy (up to
>16-fold increase) against Bacillus subtilis and E. coli compared
to the linear form, though the hemolytic activity was increased by
3-fold (152). It was also found that the antimicrobial activities of
those small Arg/Trp-rich cyclic peptides were influenced by the
self-assembling behavior of peptides at the bacterial membrane
instead of their hydrophobic surface area, amphiphilicity, and
ring size (153). In addition, a number of small cyclic D,L-alpha-
peptides (with six or eight alternating D- and L-form residues)
have also demonstrated strong antimicrobial efficacy against
Gram-positive and/or Gram-negative bacteria via self-assembly
on the bacterial membranes as organic nanotubules, which could
increase membrane permeability and disrupt transmembrane
ion potentials with resultant cell lysis (154, 155). Furthermore,
molecular dynamic simulations and biophysical assays have
provided further supportive evidence that cyclic peptides are able
to bind to negatively charged membrane more strongly than the
linear peptides and adopt a beta-sheet structure at the membrane
surface (156).
Another form of cyclization that is found abundantly in
natural HDPs, mainly in defensins, is the disulfide intramolecular
cross-link between cysteine residues, which has been shown
to enhance proteolytic stability (157–160). Inspired by the
nature, Scudiero et al. (160) engineered a 17-residue cyclic
synthetic hybrid HDP, based on the internal hydrophobic
domain of human-beta defensin (HBD)-1 and positively charged
C-terminal of HBD-3 (RRKK residues), and demonstrated
good antimicrobial efficacy against Gram-positive and Gram-
negative bacteria and herpes simplex virus, with low toxicity
and good proteolytic stability. Similarly, Mwangi et al. (161)
successfully developed a cyclic HDP-based molecule called ZY4
by introducing a disulfide bond to a derivative of cathelicidin-
BF, which is an antimicrobial peptide derived from the snake
venom of Bungarus fasciatus. This molecule was shown to
exhibit significant in vivo antimicrobial efficacy against MDR P.
aeruginosa and A. baumannii with high stability in mice lung
infection and septicemia models (161).
Incorporation With Nanoparticles (NPs)
Nanotechnology is a rapidly growing field in biotechnology
that involves characterization, manipulation and synthesis of
materials that are in nanoscales (or one billionth of meter;
10−9 m) (162). NPs, with sizes ranging from 1 to 100 nm, can
exist in many forms, including lipid-based, metal-based, carbon-
based, ceramics, semiconductor, and polymeric NPs (163). It
has increasingly been applied in the field of antimicrobials,
either employed as antimicrobial agents or nano-carriers for
drug/peptide delivery in view of their enhanced protection
against extracellular degradation, improved bioavailability, and
cell selectivity (164–167). Recently, Biswaro et al. (166) have
provided an excellent review on the role of nanotechnology in
delivering HDPs. To avoid any significant overlap, this section
aims to only recapitulate the fundamental principles of NPs and
provide some notable examples regarding the potential values of
incorporating NPs with HDPs.
In principle, there are two types of nano-delivery systems:
(a) passive delivery where the intended drugs/peptides are
encapsulated within the nanocarriers through hydrophobic
interaction without any surface modification; and (b) active
delivery where the drugs/peptides are directly conjugated with
the nanocarriers with surface modification with ligands or other
moieties to facilitate delivery to the targeted site (168). Among
all, LL-37 and its mimics are some of the most commonly
explored HDPs that have been incorporated with different types
of NPs, including polymeric NPs [e.g., poly lactic-co-glycolic acid
(PLGA)] (169), gold NP (170, 171), and magnetic NPs (172).
PLGA is a FDA-approved biodegradable and biocompatible
polymer that has demonstrated promising potential as a drug
delivery carrier (173). Chereddy et al. (169) described using
PLGA as a nanoparticle carrier for delivering a sustained
release of LL-37 treatment. Compared to PLGA or LL-37
alone, PLGA-LL37 nanoparticles were reported to expedite
the wound healing process with significantly higher collagen
deposition, re-epithelialization and neovascularization (169).
It also demonstrated better antimicrobial activity against E.
coli compared to PGLA alone, though the efficacy was lower
than LL-37 alone (169). Cruz et al. (174) similarly reported
that the encapsulated form of GIBIM-P5S9K peptide within
PLGA or polylactic acid exhibited around 20 times stronger
antimicrobial efficacy against methicillin-resistant S. aureus
(MRSA), P. aeruginosa, and E. coli when compared to the
free peptide.
In addition, gold NPs have been increasingly applied in the
field of HDPs (175). Comune et al. (171) demonstrated that
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LL-37 conjugated with gold NPs (via an additional cysteine
residue at the C-terminus of LL-37) demonstrated superior in
vitro and in vivo wound healing properties compared to LL-
37 alone. This was attributed to the prolonged phosphorylation
of epidermal growth factor receptor (EGFR) and extracellular-
signal-regulated kinase (ERK)1/2, which increased the migration
of keratinocytes. Gold NPs have also been used as nanocarriers
for other HDPs such as Esc(1-21), a derivative of a frog skin
HDP called esculentin-1a (176). Compared to Esc(1-21), it was
found that the conjugated form of Esc(1-21) with gold NPs via
a poly-ethylene glycol linker improved the antimicrobial efficacy
against P. aeruginosa by around 15-fold, with increased resistance
to proteolytic degradation (176). Certain peptides have also
demonstrated self-assembling ability as a nanocarrier for drug
delivery (166), though this is beyond the scope of our review.
Smart Design Using Artificial Intelligence
(AI) Technology
AI serves as one of the major breakthroughs in the mankind’s
history. Long been deployed in the automobile and technology
industries, AI has only started gaining traction in the field of
science and medicine, owing to the advancement in computer
power, availability of big data, publicly available neural networks,
and improvement in AI algorithms using machine learning and
deep learning (177–180). In view of the infinite chemical space
and complex SAR of natural and synthetic HDPs, AI serves as an
attractive solution to identify and predict novel peptide sequences
with potentially good antimicrobial efficacy (181–184).
To date, a number of machine learning algorithms such
as artificial neural network (ANN) (34, 182), support vector
machine (SVM)-based classifier (34, 183, 184), quantitative
matrices (34), and fuzzy K-nearest neighbor (FKNN) (185) have
been developed to search for the ideal synthetic HDPs. Cherkasov
et al. (182) trained an atomic-based QSAR model using ANN
and inductive chemical descriptors based on two large 9-mer
peptide libraries. The model was then tested against 200 peptides
that were chosen from a virtual library of 100,000 random 9-
mer peptides. The model not only successfully predicted the
antimicrobial efficacy of the synthetic peptides but also identified
potent peptide candidates (HHC-10 and HHC-36) which were
highly active against a range of Gram-positive and Gram-
negative superbugs, with low risk of toxicity (182).
On the other hand, Lee et al. (183) developed a SVM-
based classifier coupled with Pareto-optimization (186) to
deduce the functional and structural similarities of alpha-helical
HDPs. By employing antimicrobial assays and small-angle X-ray
scattering, it was found that the SVM distance to hyperplane
σ correlated strongly with the ability of HDP in generating
a negative Gaussian curvature (NGC), which is commonly
responsible for the membrane disruption mechanism of HDP
(183). Subsequently, Yount et al. (184) were able to identify a
unifying physicochemical characteristic of alpha-helical HDPs in
a 3-dimensional space, termed the alpha-core signature, using
knowledge-based annotation and pattern recognition analysis
of bioinformatics databases. The antimicrobial efficacy of this
alpha-core signature (i.e., the ability to induce NGC) was
further validated with the previously developed SVM-based
classifier (184).
DISCUSSION AND FUTURE DIRECTIONS
Since the serendipitous discovery of HDPs in nature during
early 1980s, immense research effort have been invested in
realizing the therapeutic potentials of HDPs in clinic (7). In
this review, we provided a comprehensive overview on eight
key strategies (with examples) in improving and translating the
therapeutic potentials of HDP-based treatment from bench to
bedside. Moreover, we summarized HDP derivatives that are
currently in the development pipeline.
Lessons From Previous Experience
So far, a number of HDP-based treatment have entered advanced
(phase II/III) clinical trials (Table 1) but none had reached
the market due to regulatory hurdles (27, 187). Nevertheless,
many lessons have been learnt from past experience. One of the
notable examples (as described above) is MSI-78 or pexiganan, a
magainin-derived HDP, which did not obtain the FDA approval
after failing to demonstrate any superiority to the normal
standard wound care with oral ofloxacin for infected diabetic
foot ulcers in two phase 3 trials (188). Although the discouraging
results have painted a gloomy outlook for HDP-based treatment
at that time, a closer look at the development pathway of MSI-78
has shed light on the plausible reasons accounting for the failure.
First, although the molecule demonstrated a broad-spectrum
antimicrobial activity against 3,109 clinical isolates (with an
average MIC90 of 32µg/ml or less) (63), the activity remained
considerably weaker than the conventional antibiotics (62).
Second, peptide-based treatment including MSI-78 are more
susceptible to proteolytic degradation when compared to the
conventional small molecule antibiotics. That means HDP-based
treatment need to be administered in a higher concentration to
achieve the intended in vivo efficacy, which could inevitably lead
to increased host toxicity. In addition, MSI-78 exhibits several
favorable properties over conventional antibiotics, including low
risk of developing AMR and good activity against MDR isolates
(63), but the phase 3 clinical trials of MSI-78 were conducted for
mild infective diabetic foot ulcers which did not fully capitalize
on these strengths. This highlights the importance of setting
the right research question during the development of HDP-
based treatment.
Learning from the previous (unsuccessful) experience, a
plethora of strategies have been proposed and attempted to
overcome the inherent limitations of HDP-based treatment, with
enhanced antimicrobial efficacy, proteolytic stability, and cell
selectivity (for microbial cells). Although the design of ideal
HDPs is not governed by a single overarching rule (7), it is
apparent from the literature that peptide design guided by
the fundamental principles and systematic SAR analysis is able
to yield potential efficacious peptide candidates with desired
properties (189). In fact, de novo designed synthetic peptides were
successfully developed purely based on Arg and Trp with 50%
hydrophobicity and demonstrated significantly antimicrobial
and anti-biofilm efficacies against MDR staphylococci (190).
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Proposed Strategy in Designing and
Developing HDP-Based Treatment
Based on the literature and our experience, we propose a potential
strategy in streamlining the drug discovery and development
pathway of HDP-based treatment, starting from designing
new HDP treatment to conducting well-designed pre-clinical
studies (Figure 1). So far, more than 3,000 naturally occurring
and synthetic HDPs (with reported antimicrobial and/or non-
antimicrobial functions) have been discovered (8, 9); therefore,
it would be a good strategy to use an existing template with
proven effect as a starting point for designing a new HDP-
based treatment. Alternatively, employing artificial intelligence
technology in predicting potentially efficacious molecules could
be utilized. Once a starting template is identified (either a linear
peptide or a cyclic peptide), systematic SAR analysis of the
sequence via rational substitution of specific residues is required
to optimize the antimicrobial efficacy and cell selectivity toward
microbial cells. If hybridization strategy is used, functioning
sequence of each single peptide should be first determined before
being hybridized. This is then followed by further SAR analysis
to determine the optimal sequence.
Once the efficacy and safety are optimized, the next hurdle
is to overcome the issue of proteolytic degradation, which
could be achieved through the strategies (either singularly or
in combination) mentioned in Table 2 and Figure 1. However,
it is noteworthy to mention that the beneficial effects of
these modifications may be unique to specific HDPs. In
addition, antimicrobial efficacy and/or microbial cell selectivity
of the HDPs may also be affected during the modification.
Subsequently, the potential lead compound should be validated
in in vitro conditions mimicking the physiological or host
disease environment. For instance, when designing HDP-based
treatment for corneal infection, the designed HDPs should be
tested in tear fluid or in salt of physiological concentration,
which are known to affect the efficacy and stability of HDPs.
The findings enable a better prediction of the in vivo results
and help minimize the unnecessary use of animals (191).
Finally, well-designed pre-clinical studies need to be performed
with appropriate sample size calculation and positive/negative
controls, which will increase the success rate of clinical trials.
For example, efficacy of the designed HDP needs to be compared
with antibiotic treatment that reflects the current clinical practice
for the disease of interest. Otherwise, subsequent clinical trials
are likely to fail and necessary regulatory approval will not
be obtained.
Ideally, it is best to optimize the previous steps before
progressing to the next step. For instance, validating the potential
lead compound in in vitro conditions mimicking physiological
environment is crucial before proceeding to pre-clinical studies.
Modification strategies proposed in each step may also be
applicable to other steps. For example, introduction of unnatural
AAs primarily improves the proteolytic stability but may also
enhance the antimicrobial efficacy (101), and incorporation of
HDPs with nanoparticles may reduce host toxicity as well as
improve bioavailability. In addition, several strategies may be
employed in combination to achieve the intended therapeutic
effect and stability.
There are also increasing reports examining and exploiting
the strategy of using peptide-antibiotic combination to counter
AMR, increase the lifespan of conventional antibiotics andHDPs,
as well as to reduce the undesired toxicity to host tissues (88, 192–
194). The synergistic effect of peptide-antibiotic combination
treatment is likely attributed to the different underlying
mechanism of action whereby the membrane perturbation effect
of peptides facilitates the passive diffusion of conventional
antibiotics into the cells for intracellular targeting action (192).
FIGURE 1 | A potential strategy for streamlining the drug discovery and developmental pathway of HDP-based treatment, covering from designing of new HDP
treatment to conducting well-designed pre-clinical studies.
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TABLE 2 | Summary of different strategies in translating the therapeutic potentials of host defense peptides (HDPs).
Methods HDPs template Strategies Biological effects
Residue substitution
Lee et al. (40) HP ribosomal protein 1 Pro substitution Increased antimicrobial efficacy
Wang et al. (86) LL-37 Ala/Val substitution Increased antimicrobial efficacy
Blondelle et al. (37) Melittin Trp substitution Reduced host tissue toxicity
Hybridization
Wei et al. (117) Cecropin and LL-37 Hybridization Increased antimicrobial efficacy and reduced host tissue
toxicity
Wu et al. (118) Melittin and LL-37 Hybridization Increased antimicrobial efficacy and reduced host tissue
toxicity
Boman et al. (112) Cecropin and melittin Hybridization Improved antimicrobial efficacy and reduced host tissue
toxicity
Unnatural AA
Arias et al. (101) Indolicidin Ornithine, DAB, DAP, Agb, and hArg Improved antimicrobial activity against GN and
proteolytic stability
Clemens et al. (100) Cecropin and magainin Ornithine Good antimicrobial and anti-biofilm efficacies against GP
and GN
Hicks et al. (103) Magainin Tic-Oic Increased antimicrobial activity against GP, GN and
mycobacterium and reduced host tissue toxicity
L-to-D isomerization
Jia et al. (131) Polybia-CP LDI Improved proteolytic stability and reduced host tissue
toxicity
Manabe et al. (132) Sapesin B LDI Improved antimicrobial efficacy against GP, GN and fungi
Carmona et al. (130) Pandinin 2 LDI Reduced host tissue toxicity
C- and N- terminal modifications
Saikia et al. (139) MreB N-acetylation Improved antimicrobial efficacy in salt
Falciani et al. (148) M33 C-pegylation Increased proteolytic stability
Dennison and Phoenix (143) Modelin-5 C-amidation Improved stabilization of alpha-helix and antimicrobial
efficacy
Cyclization
Mwangi et al. (161) Cathelicidin-BF Cyclization Increased antimicrobial and antibiofilm efficacies against
MDR-GN and good proteolytic stability
Scudiero et al. (160) HBD-1 and−3 Cyclization Increased proteolytic stability
Fernandez-Lopez et al. (154) De novo Cyclization of D,L-alpha peptides Increased antimicrobial efficacy
Incorporation with nanoparticles
Comune et al. (171) LL-37 Gold NP Improved wound healing
Casciaro et al. (176) Esculentin-1a Gold NP Improved antimicrobial efficacy, wound healing, and
proteolytic stability
Chereddy et al. (169) LL-37 PLGA NP Improved wound healing
Smart design with artificial intelligence technology
Yount et al. (184) 5,200 12-mer peptide sequence SVM-based classifier Identification of a unifying alpha-core signature of peptide
with good correlation with ability to generate NGC
Lee et al. (183) 572 alpha-helical peptides SVM-based classifier Accurate prediction of peptide ability to generate NGC
Cherkasov et al. (182) Random 9-mer peptide database QSAR model using ANN Generation of highly active synthetic peptides against
MDR GP and GN, with low toxicity
Three representative examples are provided for each strategy, in order of chronology.
HP, Helicobacter pylori; GP, Gram-positive bacteria; GN, Gram-negative bacteria; DAB, 2,4-diamino-butyric acid; DAP, 2,3-diamino-propionic acid (DAP); Agb, (S)-2-amino-4-
guanidinobutyric acid; hArg, homo-arginine; Tic-Oic, tetrahydroisoquionolinecarboxylic acid-octahydroindolecarboxylic acid dipeptide; HBD, Human-beta-defensin; PLGA, Poly
lactic-co-glycolic acid; SVM, support vector machine; NGC, Negative Gaussian curvature; ANN, Artificial neural network; MDR, Multidrug resistant.
Risk of AMR Related to HDP
Although HDP-based treatment has long been envisioned
as a novel solution to tackle AMR, emerging evidence are
suggesting that HDPs could also develop AMR, albeit with a
lower risk than the conventional antibiotics (7, 195). Spohn
et al. (196) have highlighted the influence of physicochemical
characteristics of HDPs, including the proportion of polar
AAs, cationicity, and hydrophobicity, on the risk of developing
HDP-related AMR, thereby providing invaluable insights into
the design of future HDPs. Reassuringly, cross resistance
between HDPs was found to be limited to those with
similar modes of action, underscoring the importance
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and necessity of having HDPs with different antimicrobial
mechanisms within the therapeutic armamentarium of
antimicrobials (197).
With the advancement in peptide design strategy, synthesis
techniques and AI technology, it is hopeful that clinical
deployment of HDP-based treatment for a range of diseases will
soon become a reality. However, further studies will need to be
conducted to decipher the mechanism of HDP-related AMR in
order to prepare for the potentially self-perpetuating vicious cycle
of AMR in the future.
METHOD OF LITERATURE SEARCH
Electronic databases, including MEDLINE (January 1950–
March 2020) and EMBASE (January 1980–March 2020), were
searched for relevant articles related to host defense peptides.
Keywords such as “host defense peptide,” “antimicrobial peptide,”
“hybrid,” “cyclization,” “unnatural amino acid,” “D-amino acid,”
“nanotechnology,” “nanoparticles,” “artificial intelligence,” and
“machine learning” were used. Only articles published in English
were included. Bibliographies of included articles were manually
screened to identify further relevant studies. The final search was
updated on 31 March 2020.
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